SRPT Stock: Price, Earnings History and SEC Filings
Sarepta Therapeutics, Inc. (SRPT) last traded at $18.62, down 3.17% on the latest session and up 2.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.42 against an analyst estimate of $0.34, a beat of 23.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
SRPT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $0.42 | $0.34 | +23.53% |
| Mar 2026 | May 6, 2026 | $3.09 | $0.39 | +692.31% |
| Dec 2025 | Feb 25, 2026 | $-3.87 | $-1.03 | -275.73% |
| Sep 2025 | Nov 3, 2025 | $-0.28 | $-0.37 | +24.32% |
SRPT beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How SRPT reacts to earnings
Across its last 8 earnings releases, SRPT moved 12.0% on average the next session, in either direction. It rose after 2 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | After close | +5.34% |
| 2026-05-06 | After close | -9.68% |
| 2026-02-25 | After close | -8.01% |
| 2026-01-12 | Before open | -11.29% |
| 2025-11-03 | After close | -33.74% |
| 2025-07-16 | After close | +19.53% |
| 2025-02-26 | After close | -3.56% |
| 2025-01-13 | Before open | -5.10% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
SRPT financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $2.2B | -$713M | -$307M | -32.5% | $-7.13 |
| 2024 | $1.9B | $235M | -$343M | 12.4% | $2.34 |
| 2023 | $1.2B | -$536M | -$577M | -43.1% | $-5.80 |
| 2022 | $933M | -$703M | -$356M | -75.4% | $-8.03 |
| 2021 | $702M | -$419M | -$482M | -59.7% | $-5.15 |
| 2020 | $540M | -$554M | $25M | -102.6% | $-7.11 |
| 2019 | $381M | -$715M | -$516M | -187.8% | – |
| 2018 | $301M | -$362M | -$450M | -120.2% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for SRPT
- 8-K · Sep 23, 2026Material agreement
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 10-Q · Aug 5, 2026
- 8-K · Jul 27, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 4, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 6, 2026
- DEF 14A · Apr 24, 2026
- 10-K · Mar 2, 2026
- 8-K · Feb 25, 2026Officer or director change
Insider filing activity
SRPT insiders filed 4 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
SRPT news
- Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth?Oct 30, 2026 · finance.yahoo.com
- Sarepta Therapeutics (SRPT) Earnings Preview Puts Its Fair Value Back In FocusOct 30, 2026 · finance.yahoo.com
- Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026 | Capitalize on $11.91B Market as Novartis, Voyager and Affinia Accelerate Engineered CapsidsOct 30, 2026 · finance.yahoo.com
- Global Gene Silencing Therapeutics Market Report 2026-2030 | Capitalize on 16.3% CAGR as Novartis, Alnylam, Ionis, Sarepta, and Arrowhead Accelerate RNA DeliveryOct 30, 2026 · finance.yahoo.com
- Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?Oct 29, 2026 · finance.yahoo.com
- Was The Run In Moderna Stock Hiding In Plain Sight?Oct 28, 2026 · trefis.com
- Has The Story Under Krystal Biotech Stock Run Out?Oct 28, 2026 · trefis.com
- Sarepta Therapeutics to Present at Upcoming Investor ConferencesOct 26, 2026 · finance.yahoo.com
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. (SRPT) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.